Johnson & Johnson

Focke Ziemssen, Michelle Sylvanowicz, Winfried M. Amoaku, Tariq Aslam, Bora Eldem, Robert P. Finger, Richard P. Gale, Laurent Kodjikian, Jean-François Korobelnik, Xiaofeng Lin, Anat Loewenstein, Paul Mitchell, Moira Murphy, David R. Owens, Nick Parker, Ian Pearce, Francisco J. Rodríguez, Jude Stern, S. James Talks, David T. Wong, Tien Yin Wong, and Jane Barratt disclose various financial interests including travel grants, personal fees, advisory board memberships, speaker fees, research sponsorship, and consulting roles with companies such as Allergan, AbbVie, Alimera, Bayer Healthcare, Biogen, Boehringer Ingelheim, Janssen, Novartis, Novo Nordisk, Merck, Regeneron, Roche, Sanofi, and others.

The article discusses the importance of SSR (Server-Side Rendering) in web development for improving performance and SEO.

Moderna, a biotech company specializing in mRNA technology, developed one of the first COVID-19 vaccines and researches treatments for infectious diseases, cancer, and rare genetic disorders. Founded in 2010, it became publicly traded in 2018 and has since expanded its mRNA-based vaccine research to include RSV, HIV, and Zika fever, among others.

Biosimilars for Humira saw low uptake in their first year, but led to lower net spending due to AbbVie’s rebates. Biosimilar prescriptions rose from 0.03% to 1.35% by Q4 2023, with net sales dropping 45% to $2.8 billion. Despite lower net prices, Humira remained cheaper than biosimilars. Concerns exist over biosimilar market sustainability and future biosimilar development.

AbbVie to acquire Nimble Therapeutics for $200M, gaining its oral peptide drugs for immune diseases and technology for peptide-based drug synthesis. Nimble's lead candidate inhibits IL-23, same target as AbbVie's Skyrizi, and is in preclinical testing. The acquisition aims to strengthen AbbVie's immunology pipeline.

The FDA granted PMA to Impella 5.5 and Impella CP heart pumps for use in pediatric patients with symptomatic ADHF and cardiogenic shock, expanding their use to those weighing at least 52 kg and 30 kg, respectively. These devices aid heart recovery by unloading the left ventricle and providing circulatory support, with potential adverse events including renal dysfunction, bleeding, and death.

Joshua K. Sabari, MD, discusses amivantamab (Ami) plus lazertinib's promise in EGFR-mutation positive NSCLC, its broad activity across EGFR mutations, and potential uses to overcome treatment resistance. He highlights the need to understand resistance mechanisms and the development of next-gen therapeutics, including EGFR and met ADCs, and EGFR and CD3 T-cell engagers, to enhance immune response in EGFR-mutant space.

FDA grants PMA to J&J MedTech's Impella 5.5 with SmartAssist and Impella CP with SmartAssist for pediatric use in acute decompensated heart failure and cardiogenic shock, with specific weight criteria for each device.